Gene Therapy Market Size & Share 2026-2035

Gene Therapy Market Size

The global gene therapy market was valued at USD 3.3 billion in 2025. The market is expected to grow from USD 4.1 billion in 2026 to USD 33.6 billion in 2035, growing at a CAGR of 26.2% during the forecast period, according to the latest report published by Global Market Insights Inc.

The growth of the market can be attributed to factors such as the expansion of gene delivery technologies, such as gene vectors, increased funding for gene therapy research, increasing incidence of cancer and other target diseases for gene therapy, increasing availability of cell & gene therapy manufacturing services, and increasing number of product approvals and launches.

Additionally, the growing prevalence of genetic and rare diseases is aiding market growth. Conditions such as spinal muscular atrophy (SMA), hemophilia, and other rare diseases have limited treatment options, making gene therapy an appealing alternative for both clinicians and patients. For example, the total number of patients with hemophilia worldwide is estimated to be around 836,000, with approximately 284,000 severe cases.

In most cases, a single gene therapy treatment can provide long-term or even curative benefit, making lifelong care and medication unnecessary. With greater awareness and diagnostic methods, more patients are being identified for gene therapy treatments and trials, which further boosts the potential market base.

Gene therapy is a therapeutic technique that involves altering or modifying an individual's genes to cure or prevent disease. It is employed to replace a faulty gene with a healthy copy of the same gene, inactivating a malfunctioning gene, or introducing a new or modified gene into the body to help treat a condition.

Between 2022 and 2024 the market witnessed considerable growth, growing from USD 1.7 billion in 2022 to USD 2.6 billion in 2024. A major trend during this period was the surge in clinical research and successful late-stage trials, which led to a wave of regulatory approvals for therapies targeting rare genetic disorders like spinal muscular atrophy and hemophilia. For instance, as per the NIH, as of March 2023, there were entries on 3,900 trials undertaken in 46 countries. This period also saw increased investments from pharmaceutical companies and venture capital firms, fueling innovation and accelerating product pipelines. Collectively, these developments strengthened investor confidence, increased the number of gene therapy candidates in development, and laid the groundwork for wider market adoption.

Major gene therapy market players include companies such as Novartis, Sarepta Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, and Ferring Pharmaceuticals. These companies drive the market with significant research and development investments, strategic partnerships, and commercialization of landmark therapies. Their success in gaining regulatory approvals and scaling up production volumes also influences pricing models and the pace of innovation across the industry.

Gene Therapy Market Trends

• A key trend shaping the gene therapy industry is the rapid approval and clinical success of several gene therapy candidates.
• For instance, as of March 2024, there are 36 gene therapies approved by the FDA, with an additional 500 in the pipeline and the expectation that 10–20 will be approved annually by 2025.
• Regulatory agencies worldwide are increasingly adopting expedited pathways, such as fast-track designations and priority reviews, to accelerate the availability of these groundbreaking treatments. This is driven by the urgent need to address rare and life-threatening genetic disorders with limited existing therapies.
• This growing number of successful clinical trial outcomes has also boosted confidence in gene therapies’ safety and efficacy, encouraging more investment and research in the field.
• Another key trend is the shift towards personalized medicine. Advances in genetic sequencing and bioinformatics are enabling the development of therapies tailored to the unique genetic makeup of individual patients. This customization improves treatment effectiveness and reduces adverse reactions, allowing therapies to be designed for very specific mutations or patient subgroups.
• Additionally, the expansion of gene therapy applications beyond rare inherited disorders into more common and complex diseases such as cancer, cardiovascular conditions, and neurological disorders is boosting market growth. Researchers and companies are increasingly focusing on harnessing gene editing and gene replacement technologies to target cancer cells or repair damaged tissues in chronic diseases. This broadening of therapeutic indications is expanding the market potential and attracting greater interest from pharmaceutical companies and investors.
• Further, increasing investments by public and private organizations are accelerating innovation and commercialization in gene therapy. For example, between 2018 and 2019, public and private institutions in the U.S. and Europe invested more than USD 15 billion in cell and gene therapies, bolstering product development pipelines.
• Thus, as the pipeline of gene therapy candidates continues to grow in various therapeutic areas, the market will continue to grow in the coming years.

Gene Therapy Market Analysis

Based on the therapy type, the gene therapy market is segmented into in vivo gene therapy and ex vivo gene therapy. The in vivo gene therapy segment dominated the market in 2025 with a revenue of USD 2.7 billion.

• In vivo gene therapy enables systemic treatment, meaning it can reach multiple sites or organs throughout the body. This is particularly beneficial for diseases that affect multiple areas or have systemic manifestations, allowing for a comprehensive therapeutic approach.
• In addition, the development of advanced delivery systems, such as viral vectors, nanoparticles, or lipid-based carriers, has improved the efficiency and specificity of in vivo gene therapy.
• These advancements enhance the targeted delivery of genetic material and improve the safety and efficacy of the therapy. This is expected to boost the segmental growth in the market.
• The ex vivo delivery method is anticipated to witness growth at 26.4% CAGR over the analysis period.
• The ex vivo delivery method is experiencing rapid growth within the gene therapy industry due to its ability to provide precise and controlled genetic modification outside the patient’s body before reintroducing the treated cells. This approach minimizes risks associated with direct in vivo delivery, such as immune reactions and off-target effects, making it especially effective for blood disorders and certain cancers.
• As a result, ex vivo methods are becoming a preferred strategy in the development of next-generation gene therapies, contributing substantially to the overall market expansion.

Based on the vector type, the gene therapy market is divided into viral vectors and non-viral vectors. The viral vectors include adeno-associated virus vectors, lentiviral vectors, retrovirus & γ-retrovirus, and other viral vectors. The viral vectors segment accounted for 88.6% of the market in 2025.

• Viral vectors hold a significant market share in the gene therapy industry since they have proven highly efficient in the delivery of genetic material to target cells.
• Viral vectors, such as adeno-associated viruses (AAV) and lentiviruses, are preferred for their ability to produce stable and long-term gene expression, an important prerequisite for therapeutic efficacy.
• Additionally, the broad use of viral vectors is supported by established manufacturing processes and a positive track record in approved gene therapies like Zolgensma and Luxturna.
• While there is ongoing research on non-viral delivery methods, viral vectors represent the gold standard, and they fuel a large part of the market's innovation and growth due to their reliability and efficacy.
• The non-viral vectors segment was valued at USD 372.3 million in 2025 and is anticipated to grow at a CAGR of 27.2% over the forecast years.
• Non-viral vectors are generally considered safer compared to viral vectors. They do not carry the risk of viral replication or integration into the host genome, which can cause unintended effects. Non-viral vectors are less likely to trigger immune responses and are associated with lower toxicity, making them attractive for clinical use.

Based on the indications, the gene therapy market is segmented into oncology, rare and genetic disorders, hematology, ophthalmology, and other indications. The oncology segment dominated the market with a market share of 46.5% in 2025 and is anticipated to grow at a CAGR of 24.2% between 2026 - 2035.

• Gene therapy allows targeted and precise delivery of therapeutic genes to cancer cells.
• By selectively modifying or killing cancer cells while sparing healthy cells, gene therapy minimizes off-target effects and reduces the toxicity associated with traditional treatments.
• Moreover, gene therapy has the potential to enhance the efficacy of traditional cancer treatments, such as chemotherapy and radiation therapy.
• Further, the growing prevalence of cancer globally supports rapid expansion of the segment. For instance, in 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the U.S. alone.
• The rare and genetic disorders segment held the second-largest market share in 2025 with a revenue of USD 1.2 billion.
• Growth is driven by the increasing adoption of gene therapies for inherited diseases such as Hemophilia A, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy.
• The segment continues to expand due to rising approvals of innovative therapies, strong investment in rare disease research, and the potential for long-term treatment benefits from a single administration.
• The ophthalmology segment is expected to witness strong growth in the gene therapy industry, driven by increasing adoption of treatments for inherited retinal disorders and other genetic eye diseases. The approval of therapies such as Luxturna has demonstrated the potential of gene therapy to provide long-term vision improvement with a single treatment.

Based on the end use, gene therapy market is classified into hospitals, specialty clinics and gene therapy centers, academic and research institutions, and other end users. The hospital segment dominated the market in 2025 with a market share of 65.8%.   

• The hospitals segment commands a significant share of the gene therapy industry, serving as a primary setting for the administration and delivery of these advanced treatments.
• Hospitals offer specialized infrastructure, skilled healthcare professionals, and supportive care required to manage the complex procedures and monitoring associated with gene therapies.
• Many hospitals are increasingly collaborating with biotech firms and participating in clinical trials, further strengthening their position in the gene therapy ecosystem.
• On the other hand, the specialty clinics and gene therapy centers segment is witnessing significant growth due to their expertise in administering complex gene therapies and managing patient follow-up.
• These centers offer specialized infrastructure, trained personnel, and advanced monitoring capabilities required for the safe delivery of gene therapy treatments.

North America Gene Therapy Market

The North America gene therapy industry dominated the gene therapy industry with a market share of 62.5% in 2025.

• Favorable regulatory environment, strong financial and investment support, advanced healthcare infrastructure, and robust research and development ecosystem are key factors driving the regional market growth.
• North America, particularly the U.S., has a strong and well-established research and development ecosystem in the field of gene therapy. It is home to leading academic institutions, research centers, and biotechnology companies that actively contribute to advancements in gene therapy research. This ecosystem fosters innovation, attracts investment, and drives the development of novel gene therapies.
• Furthermore, the prevalence of genetic disorders and complex diseases, such as cancer, in North America has created a significant market demand for innovative treatment options like gene therapy.
• Additionally, the willingness of payers to support these therapies through reimbursement programs further fuels market growth.
• The U.S. gene therapy market was valued at USD 1 billion and USD 1.2 billion in 2022 and 2023, respectively. The market size reached USD 1.9 billion in 2025, growing from USD 1.5 billion in 2024.
• The U.S. continues to dominate the gene therapy industry, driven by its robust biotechnology ecosystem, substantial research funding, and a favourable regulatory environment.
• The country is home to several leading pharmaceutical and biotech companies and benefits from a strong pipeline of innovative gene therapy candidates and cutting-edge technologies.
• Additionally, the presence of leading research institutions and extensive clinical trial activities further accelerate the development and commercialization of new therapies.

Europe Gene Therapy Market

Europe gene therapy industry accounted for USD 705.5 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe holds a significant share of the gene therapy industry due to its strong healthcare system, increasing government support, and growing investment in biotechnology development.
• The region benefits from a collaborative ecosystem involving academic institutions, research organizations, and pharmaceutical companies that accelerates the development and adoption of gene therapies.
• Within Europe, Germany holds a substantial market share in the gene therapy sector, owing to its advanced medical research facilities, strong industrial base, and supportive government policies.
• The country’s focus on precision medicine and biotechnology has fostered a dynamic environment for developing and commercializing gene therapies.
• Germany’s robust healthcare system and high patient access rates further support the uptake of innovative treatments.

Asia Pacific Gene Therapy Market

The Asia Pacific gene therapy industry is anticipated to grow at the highest CAGR of 29.9% during the analysis timeframe.

• The Asia Pacific region is witnessing rapid expansion in the gene therapy industry owing to increasing investment in healthcare, an escalating incidence of genetic diseases, and increased access to advanced medical technologies.
• Countries in the region are expanding their biotech infrastructure and accelerating clinical research through government support and global collaborations.
• Additionally, the large patient pool, growing awareness about genetic diseases, and the availability of local biotech firms are stirring up demand for new therapies.
• China dominates the Asia Pacific gene therapy market, fueled by aggressive biotech R&D spending, favorable government policies, and a rapidly expanding clinical trial landscape.
• The Chinese government has prioritized genomics and advanced therapies as part of its national health and innovation agenda, providing substantial funding and regulatory reforms to encourage growth.
• With its strong manufacturing potential, expanding healthcare infrastructure, and rising domestic demand, China is at the forefront of gene therapy innovation in the Asia Pacific region.

Latin America Gene Therapy Market

Latin American gene therapy industry is anticipated to exhibit remarkable growth during the analysis period.

• The region is emerging as a key growth center owing to its expanding healthcare sector, increasing investment in biotechnology, and growing prevalence of genetic disorders.
• The improved access to advanced medical treatments is creating a strong demand for innovative therapies.
• In addition, supportive regulatory changes and the establishment of public-private partnerships are encouraging clinical research and local development of gene therapies.

Middle East and Africa Gene Therapy Market

The Middle East & Africa gene therapy industry is expected to witness steady growth, driven by improving healthcare infrastructure, increasing investment in biotechnology research, and growing awareness of genetic and rare diseases.

• Rising adoption of advanced therapies and expanding access to specialized healthcare services are further supporting market development.
• Additionally, collaborations between regional healthcare organizations and global biotechnology companies, along with government initiatives to strengthen healthcare systems and promote innovation, are expected to accelerate the adoption of gene therapies across the region.
• Increased collaboration with global biotech firms and the government's efforts to strengthen healthcare delivery are anticipated to drive market growth.

Gene Therapy Market Share

The competitive landscape of the gene therapy industry is characterized by intense innovation and collaboration among established pharmaceutical giants, emerging biotech startups, and academic institutions. Top players such as Novartis, Sarepta Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, and Ferring Pharmaceuticals hold a combined market share of ~45% in the gene therapy industry. These players are continuously investing in research and development to expand their pipelines and enhance delivery technologies. The market also sees strategic partnerships, mergers, and acquisitions aimed at accelerating the commercialization of novel therapies and accessing new markets.

Additionally, smaller players and niche biotech firms contribute by focusing on specialized therapies and cutting-edge technologies like CRISPR and non-viral vectors. This dynamic environment fosters rapid technological advancements and competitive differentiation, driving the overall growth and diversification of the gene therapy industry.

Gene Therapy Market Companies

Prominent players operating in the gene therapy industry are as mentioned below:

• Amgen
• Bayer
• BioMarin
• bluebird bio
• Bristol Myers Squibb
• CRISPR Therapeutics
• Ferring Pharmaceuticals
• Gilead Sciences
• Krystal Biotech
• Novartis
• Orchard Therapeutics
• Pfizer
• Sarepta Therapeutics
• Spark Therapeutics (Roche)
• UniQure
• Vertex Pharmaceuticals
• Novartis

Novartis is a key player in the gene therapy market with a leading market share of ~20.5. The company is primarily known for its groundbreaking treatment Zolgensma, used to combat spinal muscular atrophy (SMA). The company’s strong focus on rare genetic disorders and its robust manufacturing capabilities have positioned it at the forefront of gene therapy innovation and commercialization.

• Vertex Pharmaceuticals
  Vertex Pharmaceuticals is a key player in the gene therapy industry, focusing on innovative treatments for genetic blood disorders such as sickle cell disease and beta-thalassemia. Their work with CRISPR-based gene editing technology exemplifies their commitment to precision medicine. With a strong pipeline and strategic partnerships, Vertex is advancing cutting-edge therapies that have the potential to transform patient outcomes in inherited diseases.

Gene Therapy Industry News

• In January 2024, Biogen and Ginkgo Bioworks announced the completion of their gene therapy collaboration involving AAV based vectors. This is expected to fuel the demand for gene therapies in the coming years.
• In December 2023, the Swiss Agency for Therapeutic Products granted approval to Libmeldy for the treatment of early-onset metachromatic leukodystrophy.
• In June 2023, the U.S. FDA granted approval to Sarepta for ELEVIDYS gene therapy to treat DMD in children of age 4-5 years.
• In May 2023, the FDA approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB) and mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
• In April 2023, REGENXBIO Inc. announced that the FDA has given fast track designation to RGX-202, a possible one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne).
• In May 2021, Biogen Inc. and Capsigen Inc. entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to deliver transformative gene therapies that address the underlying genetic causes of various CNS and neuromuscular disorders.

The gene therapy market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy Type

• In vivo gene therapy
• Ex vivo gene therapy

Market, By Vector Type

• Viral vectors 
  • Adeno-associated virus vectors
  • Lentiviral vectors
  • Retrovirus & γ-Retrovirus
  • Other viral vectors
• Non-viral vectors     

Market, By Indication

• Oncology
• Rare and genetic disorders
• Hematology
• Ophthalmology
• Other indications

Market, By End Use

• Hospitals
• Specialty clinics and gene therapy centers
• Academic and research institutions
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE